Device Trial Radar · NCT06521463
SIMPLAAFY Clinical Trial
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,857
Actual
Start
Oct 1, 2024
Primary completion
Jul 7, 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Conditions
- Atrial Fibrillation
- Stroke
- Bleeding
Interventions
WATCHMAN FLX Pro LAAC DeviceDevice
WATCHMAN FLX Pro LAAC Device Implantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduced dose NOAC Arm Primary Endpoint: Composite rate of all death, all stroke, systemic embolism, and ISTH major bleeding at 6-months after randomization in the reduced dose NOAC arm tested for non-inferiority compared to the DAPT armTime frame: 6 months after randomization
- Aspirin Arm Primary Endpoint: Composite rate of all death, all stroke, systemic embolism, and ISTH major bleeding at 6-months after randomization in the Aspirin arm tested for non-inferiority compared to the DAPT arm.Time frame: 6 months after randomization
Locations
86 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Grandview Medical Center
Birmingham, Alabama
Phoenix Cardiovascular Research Group
Phoenix, Arizona
83 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.